Michael Krzyzak
Corneal and Contact Management · Liverpool, NYNPI 1649460932
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,668 of the $2,238 with a category attached, or 74.5%. 17 manufacturers reported payments, led by Alcon at 52.9% of the total. Reporting peaked in 2020 at $680 and has fallen 87.7% since, to $84 in 2025.
Across 86 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Sun Pharmaceutical Industries Inc.$170
- Biotissue Holdings Inc.$141
- Coopervision Inc.$118
- Bausch & Lomb Americas Inc.$117
- LKC Technologies, Inc.$111
- plus $399 from 11 others
What the payments were for
- Consulting fees$57025%
- Food & beverage$1,66875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 37 | $1,184 |
| Sun Pharmaceutical Industries Inc. | 7 | $170 |
| Biotissue Holdings Inc. | 11 | $141 |
| Coopervision Inc. | 6 | $118 |
| Bausch & Lomb Americas Inc. | 6 | $117 |
| LKC Technologies, Inc. | 1 | $111 |
| ABB Con-cise Optical Group LLC | 4 | $88 |
| Johnson & Johnson Vision Care, Inc. | 2 | $62 |
| Tarsus Pharmaceuticals, Inc. | 2 | $59 |
| Kala Pharmaceuticals, Inc. | 2 | $46 |
| AbbVie(2 entities) | 2 | $39 |
| Thea Pharma Inc. | 1 | $23 |
| Menicon America Inc | 1 | $19 |
| Novartis | 1 | $19 |
| Maculogix, Inc. | 1 | $17 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
| Visioneering Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES$570
How this compares
$2,238 in reported general payments places this provider in the 60th percentile of 68 corneal and contact management providers in New York.
See all corneal and contact management providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 38 | $67,610 |
| LumiganBimatoprost | 27 | $14,497 |
| Cyclosporine | 14 | $10,934 |
| LotemaxLoteprednol Etabonate | 18 | $6,218 |
| Loteprednol Etabonate | 15 | $5,815 |
| TobradexTobramycin/Dexamethasone | 12 | $3,067 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 46 | $1,322 |
| Latanoprost | 108 | $1,263 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 20 | $718 |
| Brimonidine Tartrate | 20 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $59 | $67,61038 claims |
| AbbVieLumigan | $39 | $14,49727 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Loteprednol Etabonate | $16 | $12,03433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 68 corneal and contact management providers in New York.
Other corneal and contact management in Liverpool
- Michele LaganaHoneoye Falls$248K
- Avani DaveBuffalo$122K
- Kevin RosinNew York$59K
- Jeffrey CooperBrooklyn$52K
- Kevork NiksarliNew York$27K
- Richard MalaraBaldwinsville$8K
- David BraunSyracuse$7K
- Michael RaffBrockport$6K
- Angela DussanLong Island City$6K
- Christina ChernyNew York$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.